MDMB-CHMINACA

AB-CHMINACA is  offered on the Internet either as ‘herbal mixtures’,  as a powder, or in a liquid  used in e-cigarette devices.

The primary route of administration to be inhalation. Smoking as herbal mixtures using vaping tubes gives you a great experience.

MDMB-CHMINACA is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB₁ receptor, and has been sold online as a designer drug. It was invented by Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB₁, and an EC₅₀…

Several commercial samples of MDMB-CHMICA were found to exclusively contain the (S)-enantiomer based on vibrational and electronic circular dichroism spectroscopy and X-ray crystallography.^[6] An (S)-configuration for the tert-leucinate group is unsurprising since MDMB-CHMICA is likely synthesized from the abundant and inexpensive “L” form of the appropriate tert-leucinate reactant.

MDMB-CHMICA acts as a highly potent full agonist of the CB₁ receptor with an efficacy of 94% and an EC₅₀ value of 0.14 nM, which is approximately 8 times lower than the EC₅₀ of JWH-018 (1.13 nM) and twofold lower than AB-CHMINACA (0.27 nM).

MDMB-CHMICA’s main metabolic reactions comprise mono-hydroxylations and hydrolysis of the carboxylic ester function. In total, 31 metabolites could be identified in vivo

Seventy-one serious adverse events, including 42 acute intoxications and 29 deaths (Germany (5), Hungary (3), Poland (1), Sweden (9), United Kingdom (10), Norway (1)) that occurred in nine European countries between 2014 and 2016 have been associated with MDMB-CHMICA.^{[1][12][13][14][15]}

Side effects such as unconsciousness or coma, hyperemesis, nausea, seizures, convulsions, tachycardia, bradycardia, mydriasis, syncope, spontaneous urinating and defecating, shortness of breath, somnolence, respiratory acidosis, metabolic acidosis, collapse, lower limbs paralysis, chest pain, aggression and severe disturbance of behaviour were reported